Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Mar 20, 2007
Change of Director's Interest Notice
Mar 16, 2007
Substantial Security Holder Notice
Mar 16, 2007
Preliminary Final Report
Feb 26, 2007
Neuren scientist receives Laureate award
Feb 19, 2007
Appendix 3B - ESOP options exercised
Feb 13, 2007
Further Validation of NNZ-2566 as TBI Treatment
Jan 31, 2007
Commitments Test Entity - Fourth Quarter Report
Jan 31, 2007
US FDA approves Phase 3 IND for Glypromate Trial
Jan 29, 2007
Appendix 3B - escrow period ending 3 February 2007
Jan 17, 2007
Appendix 3B
Previous
1
2
3
4
5
6
Next